0001434265--12-31 2022 Q2 false Genmab A/S 6-K 2022-06-30 0001434265 2022-01-01 2022-06-30 0001434265 gmab:PropertiesMember 2022-06-30 0001434265 gmab:IfrsEquipmentMember 2022-06-30 0001434265 gmab:PropertiesMember 2021-06-30 0001434265 gmab:IfrsEquipmentMember 2021-06-30 0001434265 gmab:TepezzaMember gmab:RoyaltiesRevenueMember 2022-01-01 2022-06-30 0001434265 gmab:OtherRoyaltyProductMember gmab:RoyaltiesRevenueMember 2022-01-01 2022-06-30 0001434265 gmab:KesimptaMember gmab:RoyaltiesRevenueMember 2022-01-01 2022-06-30 0001434265 gmab:DarzalexMember gmab:RoyaltiesRevenueMember 2022-01-01 2022-06-30 0001434265 gmab:RoyaltiesRevenueMember 2022-01-01 2022-06-30 0001434265 gmab:ReimbursementIncomeMember 2022-01-01 2022-06-30 0001434265 gmab:OtherCollaborationPartnersMember 2022-01-01 2022-06-30 0001434265 gmab:MilestonePaymentsRevenueMember 2022-01-01 2022-06-30 0001434265 gmab:CollaborationRevenueMember 2022-01-01 2022-06-30 0001434265 gmab:AgreementsWithSeagenMember 2022-01-01 2022-06-30 0001434265 gmab:AgreementsWithRocheMember 2022-01-01 2022-06-30 0001434265 gmab:AgreementsWithNovartisMember 2022-01-01 2022-06-30 0001434265 gmab:AgreementsWithJanssenMember 2022-01-01 2022-06-30 0001434265 gmab:AgreementsWithBointechMember 2022-01-01 2022-06-30 0001434265 gmab:TepezzaMember gmab:RoyaltiesRevenueMember 2021-01-01 2021-06-30 0001434265 gmab:OtherRoyaltyProductMember gmab:RoyaltiesRevenueMember 2021-01-01 2021-06-30 0001434265 gmab:KesimptaMember gmab:RoyaltiesRevenueMember 2021-01-01 2021-06-30 0001434265 gmab:DarzalexMember gmab:RoyaltiesRevenueMember 2021-01-01 2021-06-30 0001434265 gmab:RoyaltiesRevenueMember 2021-01-01 2021-06-30 0001434265 gmab:ReimbursementIncomeMember 2021-01-01 2021-06-30 0001434265 gmab:MilestonePaymentsRevenueMember 2021-01-01 2021-06-30 0001434265 gmab:AgreementsWithSeagenMember 2021-01-01 2021-06-30 0001434265 gmab:AgreementsWithRocheMember 2021-01-01 2021-06-30 0001434265 gmab:AgreementsWithNovartisMember 2021-01-01 2021-06-30 0001434265 gmab:AgreementsWithJanssenMember 2021-01-01 2021-06-30 0001434265 gmab:AgreementsWithBointechMember 2021-01-01 2021-06-30 0001434265 gmab:AgreementsWithAbbvieMember 2021-01-01 2021-06-30 0001434265 gmab:CurevacCollaborationMember 2022-06-30 0001434265 gmab:BoltBiotherapeuticsIncMember 2022-06-30 0001434265 gmab:CurevacCollaborationMember 2021-12-31 0001434265 gmab:BoltBiotherapeuticsIncMember 2021-12-31 0001434265 ifrs-full:SharePremiumMember 2022-01-01 2022-06-30 0001434265 ifrs-full:SharePremiumMember 2021-01-01 2021-06-30 0001434265 gmab:OtherInvestmentMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2022-06-30 0001434265 gmab:OtherInvestmentMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2022-06-30 0001434265 gmab:MarketableSecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2022-06-30 0001434265 gmab:OtherInvestmentMember ifrs-full:AtFairValueMember 2022-06-30 0001434265 gmab:MarketableSecuritiesMember ifrs-full:AtFairValueMember 2022-06-30 0001434265 gmab:OtherInvestmentMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2021-12-31 0001434265 gmab:OtherInvestmentMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2021-12-31 0001434265 gmab:MarketableSecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2021-12-31 0001434265 gmab:OtherInvestmentMember ifrs-full:AtFairValueMember 2021-12-31 0001434265 gmab:MarketableSecuritiesMember ifrs-full:AtFairValueMember 2021-12-31 0001434265 ifrs-full:SharePremiumMember 2022-06-30 0001434265 ifrs-full:RetainedEarningsMember 2022-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-06-30 0001434265 ifrs-full:IssuedCapitalMember 2022-06-30 0001434265 ifrs-full:SharePremiumMember 2021-12-31 0001434265 ifrs-full:RetainedEarningsMember 2021-12-31 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001434265 ifrs-full:IssuedCapitalMember 2021-12-31 0001434265 ifrs-full:SharePremiumMember 2021-06-30 0001434265 ifrs-full:RetainedEarningsMember 2021-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-06-30 0001434265 ifrs-full:IssuedCapitalMember 2021-06-30 0001434265 ifrs-full:SharePremiumMember 2020-12-31 0001434265 ifrs-full:RetainedEarningsMember 2020-12-31 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001434265 ifrs-full:IssuedCapitalMember 2020-12-31 0001434265 gmab:PropertiesMember 2022-01-01 2022-06-30 0001434265 gmab:IfrsEquipmentMember 2022-01-01 2022-06-30 0001434265 gmab:PropertiesMember 2021-01-01 2021-06-30 0001434265 gmab:IfrsEquipmentMember 2021-01-01 2021-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-06-30 0001434265 2021-06-30 0001434265 2022-04-01 2022-06-30 0001434265 2021-04-01 2021-06-30 0001434265 gmab:IfrsRestrictedStockUnitsRSUsMember 2022-01-01 2022-06-30 0001434265 gmab:IfrsRestrictedStockUnitsRSUsMember 2021-01-01 2021-06-30 0001434265 gmab:RestrictedStockUnitsRSUsMember 2022-01-01 2022-06-30 0001434265 gmab:StockRepurchaseAuthorization2021Member 2022-01-01 2022-06-30 0001434265 gmab:StockRepurchaseAuthorization2019Member 2022-01-01 2022-06-30 0001434265 gmab:StockRepurchaseAuthorization2016Member 2022-01-01 2022-06-30 0001434265 gmab:DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember 2022-03-29 2022-03-29 0001434265 2020-12-31 0001434265 ifrs-full:CurrencyRiskMember currency:USD 2022-01-01 2022-06-30 0001434265 ifrs-full:CurrencyRiskMember currency:GBP 2022-01-01 2022-06-30 0001434265 ifrs-full:CurrencyRiskMember currency:EUR 2022-01-01 2022-06-30 0001434265 ifrs-full:CurrencyRiskMember currency:DKK 2022-01-01 2022-06-30 0001434265 ifrs-full:CurrencyRiskMember 2022-01-01 2022-06-30 0001434265 ifrs-full:CurrencyRiskMember currency:USD 2021-01-01 2021-12-31 0001434265 ifrs-full:CurrencyRiskMember currency:GBP 2021-01-01 2021-12-31 0001434265 ifrs-full:CurrencyRiskMember currency:EUR 2021-01-01 2021-12-31 0001434265 ifrs-full:CurrencyRiskMember currency:DKK 2021-01-01 2021-12-31 0001434265 ifrs-full:CurrencyRiskMember 2021-01-01 2021-12-31 0001434265 gmab:TripleaRatingMember ifrs-full:CreditRiskMember 2022-06-30 0001434265 gmab:TripleaRatingMember ifrs-full:CreditRiskMember 2021-12-31 0001434265 gmab:WarrantsMember 2022-01-01 2022-06-30 0001434265 gmab:WarrantsMember 2021-01-01 2021-06-30 0001434265 gmab:StockRepurchaseAuthorization2021Member 2022-06-30 0001434265 gmab:StockRepurchaseAuthorization2019Member 2022-06-30 0001434265 gmab:StockRepurchaseAuthorization2016Member 2022-06-30 0001434265 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2022-03-29 2022-03-29 0001434265 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001434265 ifrs-full:RetainedEarningsMember 2021-01-01 2021-06-30 0001434265 2022-06-30 0001434265 gmab:OfficeAndLaboratorySpaceMember country:DK 2022-06-30 0001434265 gmab:MijkeZachariasseMartinSchultzAndTakahiroHamataniMember 2022-03-29 2022-03-29 0001434265 gmab:ElizabethOfarrellMember 2022-03-29 2022-03-29 0001434265 2021-12-31 0001434265 2021-01-01 2021-06-30 iso4217:DKK gmab:item gmab:director xbrli:shares xbrli:pure iso4217:DKK xbrli:shares gmab:EquityInstruments

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​
FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF AUGUST 2022

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Yes ◻ No ⌧

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Yes ◻ No ⌧

Exhibit 99.1 to this report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statement on Form S-8 (File No. 333-232693) and in the outstanding prospectus contained in such registration statement.

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​ | ​ | ​
​ | GENMAB A/S
​ | ​ | ​
​ | BY: | /s/ Anthony Pagano
​ | ​ | Name: Anthony Pagano
​ | ​ | Title: Executive Vice President & Chief Financial Officer

​

DATE: August 10, 2022

​

​

EXHIBIT INDEX

A |
Exhibit | Description of Exhibit
​ | ​
99.1 | Interim Report Dated August 10, 2022
101.INS | XBRL Instance Document
101.SCH | XBRL Taxonomy Extension Schema Document
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB | XBRL Taxonomy Extension Labels Linkbase Document
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document

​

​

​